GH Research PLC - (GHRS) closed at $20.50 on November 2, 2026, down 1.7% from the previous close, on volume of 529,730 shares (30-day average 320,922).
Data as of November 2, 2026.
2-Nov-2026
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
Globe Newswire (Thu, 6-Aug 7:00 AM ET)
Market Chameleon (Mon, 20-Apr 5:17 AM ET)
Market Chameleon (Thu, 5-Mar 4:10 AM ET)
GH Research Awaits Key FDA Decision on GH001 as Phase 3 Depression Trial Advances
Market Chameleon (Mon, 5-Jan 5:31 AM ET)
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment for depression. Its initial focus is on developing novel and proprietary mebufotenin therapies for the treatment of patients with Treatment-Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate, and GH002, a proprietary intravenous mebufotenin product candidate. The group has only a single segment: Research and Development.
GH Research PLC - trades on the NASDAQ stock market under the symbol GHRS.
As of November 2, 2026, GHRS stock price declined to $20.50 with 529,730 million shares trading.
GHRS has a beta of 1.65, meaning it tends to be more sensitive to market movements. GHRS has a correlation of 0.12 to the broad based SPY ETF.
GHRS has a market cap of $1.41 billion. This is considered a Small Cap stock.
In the last 3 years, GHRS traded as high as $31.44 and as low as $5.05.
The top ETF exchange traded funds that GHRS belongs to (by Net Assets): IBB, PSIL, EIRL, BBC, IBBQ.
GHRS has outperformed the market in the last year with a price return of +63.5% while the SPY ETF gained +11.7%. However, in the short term, GHRS had mixed performance relative to the market. It has underperformed in the last 3 months, returning -27.8% vs +1.7% return in SPY. But in the last 2 weeks, GHRS shares have fared better than the market returning +12.9% compared to SPY -1.5%.
GHRS support price is $20.03 and resistance is $21.69 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GHRS shares will trade within this expected range on the day.
